

Date: October 2, 2025

To: Iowa Vaccines for Children (VFC) Program Providers

From: Iowa VFC Program

Re: Vaccine Update – Enflonsia (Clesrovimab-cfor) Vaccine

Effective October 2, 2025, the Iowa VFC Program will implement and allow ordering of Enflonsia (Clesrovimab-cfor).

Enflonsia (Clesrovimab-cfor) is a long-acting monoclonal antibody for the prevention of respiratory syncytial virus (RSV) among infants aged <8 months born during or entering their first RSV season who are not protected by maternal vaccination. There is no preferential recommendation between Beyfortus (Nirsevimab) and Enflonsia (Clesrovimab-cfor) for infants <8 months of age.

A detailed summary is available on the [VFC Program Website](#) and includes information on use, dosage, schedule, and contraindications.

VFC Program Ordering

Due to the anticipated limited allocation of Enflonsia, clinics should order small quantities initially. Based on limited inventory, it may be necessary for the Program to reduce provider orders. Vaccine wastage and unnecessary vaccine expiration may result in restitution per the [Vaccine Restitution Policy](#).

For questions, contact the Iowa VFC Program at iowaVFC@hhs.iowa.gov.